Verdun, Canada Clinical Trials

A listing of Verdun, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 139 clinical trials
Featured trial
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on stable symptomatic PD medication.

dopamine transporter
Montreal Neurological Institute and Hospital
 (3.8 away) Contact site
  • 09 May, 2022
  • +108 other locations
Featured trial
We are currently recruiting participants for the BLUEPRINT study. This study investigates the effectiveness, safety, and tolerability of the drug BLU-5937 for chronic itch in people with eczema.

The BLUEPRINT study consists of taking two tablets orally, twice a day, for a period of 4 weeks. This treatment is experimental. You will have 50% chance to receive BLU-5937 and 50% chance to receive the placebo. There will be a total of 5 visits at the clinic and 2 …

atopic dermatitis
atopic dermatitis/eczema
adult atopic dermatitis
Innovaderm Research
 (4.9 away) Contact site
  • 10 Dec, 2020
  • +24 other locations
Featured trial
We are currently recruiting patients with Palmoplantar Pustulosis (PPP). This study investigates the Efficacy and safety of ANB019.

The study drug consists of a sub-cutaneous investigational treatment or a placebo, that will be administered on Day 1, followed by 3 doses of the study treatment on Days 29, Day 57 and Day 85. Several blood samples will be collected throughout the study. Your participation in the biopsy portion …

skin disease
skin disorder
Dr. David Gratton Dermatologue Inc.
 (2.9 away) Contact site
  • 22 Dec, 2020
  • +23 other locations
Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC

Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of disease is initially having radiation therapy at the same time as chemotherapy (with a drug called cisplatin), with no additional therapy afterwards

oropharyngeal carcinoma
human papillomavirus
neutrophil count
The Research Institute of the McGill University
 (1.9 away) Contact site
  • 14 Mar, 2022
  • +24 other locations
Non-Steroidal or Opioid Analgesia Use for Children With Musculoskeletal Injuries (No OUCH)

Musculoskeletal (MSK) injuries, including limb injuries, are the most common cause for Emergency Department (ED) visits for children with pain. Broken arms and legs are known to cause moderate to severe pain in most children, yet previous research shows that children's pain in the emergency department is still under-treated. Further, …

CHU Sainte-Justine
 (3.2 away) Contact site
  • 07 Feb, 2022
  • +11 other locations
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032)

This is an open-label, multi-institutional phase II randomized study comparing neoadjuvant radiotherapy followed by surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm.

McGill University Health Centre
 (1.9 away) Contact site
  • 06 Apr, 2022
  • +15 other locations
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy nave pediatric patients with progressive Low Grade Glioma aged 6 months to less than18 years of age at the time of initiation of therapy. Participants will be randomized to Arm …

auditory test
progressive disease
platelet count
Centre Hospitalier Universitaire Sainte-Justine
 (3.2 away) Contact site
  • 27 Jan, 2022
  • +23 other locations
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic NSCLC.

Centre Hospitalier de L'Universite de Montreal (CHUM)
 (3.2 away) Contact site
  • 25 Mar, 2022
  • +28 other locations
Study of ARO-APOC3 in Adults With Mixed Dyslipidemia (MUIR)

Participants who have met all protocol eligibility criteria will be randomly assigned to treatment (ARO-APOC3 or placebo) in a double-blind fashion and will be evaluted for safety and efficacy over 48 weeks. Participants will be counseled to remain on a specified diet throughout the study, as recommended by the Investigator …

Institut de Recherches Cliniques de Montreal
 (4.0 away) Contact site
  • 19 Apr, 2022
  • +27 other locations
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma

FIREFLY-1 is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma harboring a known BRAF alteration.

McGill University
 (3.4 away) Contact site
  • 07 Dec, 2021
  • +22 other locations